168 HR buprenorphine 0.0075 MG/HR Transdermal System
- RxCUI
- 1542997
- RxNorm name
- 168 HR buprenorphine 0.0075 MG/HR Transdermal System
- Display name
- Buprenorphine (Transdermal)
- Full name
- 168 HR buprenorphine 0.0075 MG/HR Transdermal System
- Term type
- SCD
- Status
- Active
- Strength
- 7.5 mcg/hr
- Dose form
- 168 HR Patch
- Route
- Transdermal
- Updated
- 2026-11-19 15:42:26
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 082014
- Active start
- 082014
- Multiple ingredient
- NO
- Branded
- NO
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| buprenorphine | 0.0075 MG / 1 HR | buprenorphine | buprenorphine |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Transdermal System | 316987 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| buprenorphine | 1819 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | 168 HR buprenorphine 0.0075 MG/HR Transdermal System | 1 | NAMES |
| RxNorm Name | 168 HR buprenorphine 0.0075 MG/HR Transdermal System | 1 | NAMES |
| RxNorm Synonym | 2 | NAMES | |
| TTY | SCD | 1 | ATTRIBUTES |
| SPL_SET_ID | 5 | CODES | |
| RxCUI | 1542997 | 1 | CODES |
| MMSL_CODE | 2 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 0093-3239-40 | 0093-3239 | Buprenorphine Buprenorphine | Teva Pharmaceuticals USA, Inc. | ANDA204937 |
| 3215-1522-04 | 3215-1522 | Buprenorphine Buprenorphine | Aveva Drug Delivery Systems Inc. | ANDA210272 |
| 42858-353-40 | 42858-353 | Buprenorphine Buprenorphine | Rhodes Pharmaceuticals LLC | NDA021306 |
| 50742-373-04 | 50742-373 | Buprenorphine Buprenorphine | INGENUS PHARMACEUTICALS, LLC | ANDA210272 |
| 69238-1505-2 | 69238-1505 | Buprenorphine Buprenorphine | Amneal Pharmaceuticals NY LLC | ANDA211586 |
Drugs@FDA Applications#
| Application | NDC | Name | Marketing category | Labeler |
|---|---|---|---|---|
| ANDA204937 | 0093-3239 | Buprenorphine Buprenorphine | ANDA | Teva Pharmaceuticals USA, Inc. |
| ANDA210272 | 3215-1522 | Buprenorphine Buprenorphine | ANDA | Aveva Drug Delivery Systems Inc. |
| NDA021306 | 42858-353 | Buprenorphine Buprenorphine | NDA AUTHORIZED GENERIC | Rhodes Pharmaceuticals LLC |
| ANDA211586 | 69238-1505 | Buprenorphine Buprenorphine | ANDA | Amneal Pharmaceuticals NY LLC |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | 2738feae-316e-426f-971c-5f142ac01b60 | 2026-05-29 | Boxed warning, Warnings, Adverse reactions | 42858-353-40 42858-353 42858035340 1542997 |
| Buprenorphine | BUPRENORPHINE | Teva Pharmaceuticals USA, Inc. | 36995ce3-b515-447b-baa9-aa14f84060d8 | 2026-05-12 | Boxed warning, Warnings, Adverse reactions | 0093-3239-40 0093-3239 00093323940 1542997 |
| Butrans | BUPRENORPHINE | Knoa Pharma LLC | 794aa355-66de-41b8-aedf-f2c40f6bc664 | 2026-05-01 | Boxed warning, Warnings, Adverse reactions | 1542997 |
| Buprenorphine | BUPRENORPHINE | INGENUS PHARMACEUTICALS, LLC | 186e3be6-8bc0-4bb9-96f5-429d53632f45 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | 50742-373-04 50742-373 50742037304 1542997 |
| Buprenorphine | BUPRENORPHINE | Aveva Drug Delivery Systems Inc. | 1aae9b13-7431-42ef-8558-14a2325820e6 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | 3215-1522-04 3215-1522 03215152204 1542997 |
| Buprenorphine | BUPRENORPHINE | Amneal Pharmaceuticals NY LLC | c7d079fb-507f-436f-b794-2171b7d97067 | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | 69238-1505-2 69238-1505 69238150502 1542997 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 794aa355-66de-41b8-aedf-f2c40f6bc664 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 32 | These highlights do not include all the information needed to use BUTRANS ® safely and effectively. See full prescribing information for BUTRANS. BUTRANS ® (buprenorphine) transdermal system, CIII Initial U.S. Approval: 1981 | 20260501 |
| 36995ce3-b515-447b-baa9-aa14f84060d8 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 20 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | 20240531 |
| c7d079fb-507f-436f-b794-2171b7d97067 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 19 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | 20260109 |
| 2738feae-316e-426f-971c-5f142ac01b60 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 17 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. Buprenorphine Transdermal System, CIII Initial U.S. Approval: 1981 | 20260529 |
| 186e3be6-8bc0-4bb9-96f5-429d53632f45 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 4 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | 20260428 |
| 1aae9b13-7431-42ef-8558-14a2325820e6 | buprenorphine 7.5 MCG/HR 7 Day Transdermal System [PSN] · 168 HR buprenorphine 0.0075 MG/HR Transdermal System [SCD] · buprenorphine 7.5 MCG/HR 7 Day Transdermal Patch [SY] · buprenorphine 7.5 MCG/HR 7 Day Transdermal System [SY] | 4 | 3 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | 20260428 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| 2738feae-316e-426f-971c-5f142ac01b60 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. Buprenorphine Transdermal System, CIII Initial U.S. Approval: 1981 | Rhodes Pharmaceuticals LLC | LTS Lohmann Therapy Systems Corp. | LTS Lohmann Therapie-Systeme AG | 20260529 |
| 2738feae-316e-426f-971c-5f142ac01b60 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. Buprenorphine Transdermal System, CIII Initial U.S. Approval: 1981 | Rhodes Pharmaceuticals LLC | LTS Lohmann Therapy Systems Corp. | LTS Lohmann Therapie-Systeme AG | 20260526 |
| 36995ce3-b515-447b-baa9-aa14f84060d8 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | Teva Pharmaceuticals USA, Inc. | 20260512 |
| 186e3be6-8bc0-4bb9-96f5-429d53632f45 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems Inc. | 20260428 |
| 1aae9b13-7431-42ef-8558-14a2325820e6 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | 20260428 |
| 186e3be6-8bc0-4bb9-96f5-429d53632f45 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems Inc. | 20260323 |
| 2738feae-316e-426f-971c-5f142ac01b60 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. Buprenorphine Transdermal System, CIII Initial U.S. Approval: 1981 | Rhodes Pharmaceuticals L.P. | LTS Lohmann Therapy Systems Corp. | LTS Lohmann Therapie-Systeme AG | 20260203 |
| c7d079fb-507f-436f-b794-2171b7d97067 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | Amneal Pharmaceuticals NY LLC | 20260109 |
| 36995ce3-b515-447b-baa9-aa14f84060d8 | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | Teva Pharmaceuticals USA, Inc. | 20240531 |
| 17ad1a5b-e89f-d5a3-d15b-2eb48bcded7d | These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: 1981 | Apotex Corp. | Aveva Drug Delivery Systems Inc. | 20230706 |
| 37ca3288-80e0-5b4e-e063-6394a90a2498 | BUPRENORPHINE transdermal system, CIII | Praxis, LLC | 20230101 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | N07BC | Drugs used in opioid dependence | ATC1-4 | buprenorphine | |
| ATC | N02AE | Oripavine derivatives | ATC1-4 | buprenorphine | |
| FDASPL | N0000175689 | Partial Opioid Agonist | EPC | has_epc | buprenorphine |
| FDASPL | N0000175685 | Partial Opioid Agonists | MOA | has_moa | buprenorphine |
| MEDRT | D002047 | Buprenorphine | CHEM | has_ingredient | buprenorphine |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | buprenorphine |
| MEDRT | D006556 | Heroin Dependence | DISEASE | may_treat | buprenorphine |
| MEDRT | D010146 | Pain | DISEASE | may_treat | buprenorphine |
| MEDRT | N0000000154 | Opioid Antagonists | MOA | has_moa | buprenorphine |
| MEDRT | N0000175685 | Partial Opioid Agonists | MOA | has_moa | buprenorphine |
| MEDRT | N0000008768 | Decreased Organized Electrical Activity | PE | has_pe | buprenorphine |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 0.0075 MG/HR |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | QUANTITY | 168 HR |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 3 |
| CODES | ANDA | ANDA204937 |
| CODES | ANDA | ANDA210272 |
| CODES | ANDA | ANDA211586 |
| CODES | VUID | 4033704 |
| NAMES | Prescribable Synonym | buprenorphine 7.5 MCG/HR 7 Day Transdermal System |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | Veterans Health Administration National Drug File |